GTCM
APRE icon

Gyon Technologies Capital Management’s Aprea Therapeutics APRE Stock Holding History

Gyon Technologies Capital Management’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,029
Closed -$38K – 464
2022
Q1 		$38K Buy
+1,029
New +$42.2K 0.03% 258
2021
Q1 		– Sell
-2,090
Closed -$206K – 399
2020
Q4 		$206K Buy
+2,090
New +$994K 0.07% 317

Other funds holding APRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Gyon Technologies Capital Management's APRE Position: Q2 2022 in Review

Gyon Technologies Capital Management sold out of Aprea Therapeutics (APRE) in Q2 2022, closing a stake of 1,029 shares — an estimated $38K sold.

Gyon Technologies Capital Management first reported a position in APRE in Q4 2020 and held it in 2 quarters. The position peaked at $206K in Q4 2020. 33 funds tracked by Wall St. Rank hold APRE as of Q2 2022.

  • Gyon Technologies Capital Management reported no remaining Aprea Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 1,029 Aprea Therapeutics shares in Q2 2022, an estimated $38K.
  • Gyon Technologies Capital Management first reported a position in Aprea Therapeutics in Q4 2020 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Aprea Therapeutics position peaked at $206K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.